Serum
8
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.
Neutralizing Power of Serum Antibodies - 2
Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients
Relationship Between Serum Vitamin D and Atherosclerosis in Hemodialysis Patients
Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis
Evaluation of Discarded Laboratory Pathological Specimens and Media
Effects of Non-surgical Periodontal Therapy on Severe Periodontitis and Hyperlipidemia